At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 56 enrolled
Drug / intervention
LY3493269 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Subcutaneous Doses of LY3493269 in Patients With Type 2 Diabetes Mellitus
In Brief
A Phase 1 clinical trial evaluating LY3493269, Dulaglutide, and 1 other intervention for Diabetes Mellitus, Type 2. Completed, enrolled 56 participants across 3 sites.
Detailed Summary
The main purpose of this study is to determine the side effects related to LY3493269 in participants with type 2 diabetes. Blood tests will be performed to check concentrations of LY3493269 in the bloodstream. Each enrolled participant will receive LY3493269, dulaglutide, or placebo. The study will last up to approximately 16 weeks for each participant and may include up to 11 visits.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartAug 2020
Primary CompletionMar 2021
TodayJul 2026
First PostedAug 17, 2020
Enrollment StartAug 25, 2020
Primary CompletionMar 9, 2021
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 5.9 years ago
Interventions
LY3493269drug
Administered SC
Dulaglutidedrug
Administered SC
Placebodrug
Administered SC